The Institute is expected to begin operations in late 2020 and will be a state-of-the-art facility for the research and production of next-generation, life-saving medical isotopes and radiopharmaceuticals
Speaking at the 11th International Symposium on Targeted Alpha Therapy (TAT 11) in Ottawa, the organizations announced today a new partnership that brings together their respective R&D, manufacturing, and commercialization strengths to develop innovative, personalized cancer treatments.
An international collaboration, including several members from TRIUMF’s Theory Department, today published results that may dispel a long-standing mystery surrounding β-decay rates.
As we round the corner on TRIUMF’s 50th birthday, we also look back at one of its most important and enduring relationships and a team who has stewarded a critical contribution to the lab’s growth and success for over four decades.
On Wednesday, February 20th, a group of ARIEL colleagues joined together for a team photo in celebration of a key achievement in our work on ARIEL: the completion of the electron beam line dog leg and proton cave shielding.
